Chlamydia pneumoniae and atherosclerosis: Critical assessment of diagnostic methods and relevance to treatment studies

Clinical Microbiology Reviews

Volumn 15, Issue 1, 2002, Pages 1-20

  Boman, Jens ^a   Hammerschlag, Margaret R ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; GATIFLOXACIN; MACROLIDE; QUINOLONE DERIVATIVE; ROXITHROMYCIN; TETRACYCLINE;

ATHEROSCLEROSIS; BACTERIUM IDENTIFICATION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CELL CULTURE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOLERABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; VASCULAR TISSUE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ARTERIOSCLEROSIS; CHILD; CHILD, PRESCHOOL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; INFANT; MALE; MICE; RABBITS;

BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; RICKETTSIALES;

EID: 0036144354     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.15.1.1-20.2002     Document Type: Review

References (155)

1. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease
2. Evaluation of C-reactive protein, and inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction
3. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery
4. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens
5. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens
6. Detection of Chlamydia pneumoniae but not cytnmegalovirus in occluded saphenous vein coronary artery bypass grafts
7. Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease
8. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes
9. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms
10. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection
11. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate
12. Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas
13. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors
14. Molecular diagnosis of Chlamydia pneumoniae infection
15. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells
16. Chlamydia pneumoniae (and other infective agents) in atherosclerosis and acute coronary syndromes. How good is the evidence?
17. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues
18. Nucelotide sequence and taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae IOL-207
19. Chlamydiapneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery
20. Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-q-wave acute myocardial infarction
21. Chronic infections and coronary heart disease: Is there a link?
22. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: Population based study of coronary heart disease
23. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
24. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
25. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis
26. Molecular evaluation of serial isolates from patients with persistent Chlamydiapneumoniae infections
27. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA), and the Laboratory Centre for Disease Control (Canada)
28. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial
29. Infection and coronary heart disease
30. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis
31. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection?
32. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction
33. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR
34. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia
35. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model?
36. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment
37. The role of Chlamydia pneumoniae in cardiovascular disease
38. Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis
39. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries
40. Chlamydiapneumoniae infection in circulating human monocytes is refractory to antibiotic treatment
41. The proatherogenic properties of lipoprotein (a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies
42. A new respiratory tract pathogen: Chlamydia pneumoniae strain
43. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery
44. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
45. Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease
46. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study
47. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study
48. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma
49. Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma?
50. The in vitro activity of a group of broad spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis
51. Persistent infection with Chlamydia pneumoniae following acute respiratory illness
52. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
53. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae
54. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: A review
55. Picornavirus proteins share antigenic determinants with heat shock proteins 60/65
56. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children
57. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction-enzyme immunoassay and culture
58. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis
59. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen
60. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline
61. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease
62. Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses
63. Description and status of the azithromycin and coronary events study (ACES)
64. Low prevalence of Chlarmydia pneumoniae in atherectomy specimens from patients with coronary heart disease
65. Interference of immunoglobulin G (IgG) antibodies in IgA determinations of Chlamydia pneumoniae by microimmunofluorescence test
66. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms
67. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves
68. Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease
69. A seroepidemiologic study of Chlamydin pneumoniae in Rhode Island. Evidence of serologic cross-reactivity
70. The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations
71. Relation of C-reactive protein and coronary heart disease in the MRFIT nested casecontrol study
72. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
73. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain
74. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34years old)
75. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction
76. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection
77. Antibody response to Chlamydia pneumoniae infection in children with respiratory illness
78. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model
79. Ultrastructural study of Chlamydia pneumoniae in a continuous infection model
80. Effect of Azithromycin and clarithromycin on Chlamydia pneumoniae in a continuous infection model
81. Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR)
82. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections
83. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis
84. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease
85. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients
86. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease
87. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction
88. Serologic cross-reactions between Bartonella and Chlamydia species: Implications for diagnosis
89. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease
90. Antibiotics and risk of subsequent first-time acute myocardial infarction
91. Antibiotics in the prevention and treatment of coronary heart disease
92. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study
93. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis
94. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and nondiabetic subjects in Finland
95. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease
96. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
97. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study
98. Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction
99. Infections and atherosclerosis: New clues from an old hypothesis
100. Chlamydia pneumoniae infection and incident coronary heart disease: The Atherosclerosis Risk in Communities Study
101. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement
102. Comparative analysis of the putative amino acid sequences of chlamydial heat shock protein 60 and Escherichia coli GroEL
103. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications
104. Diseases of the arteries
105. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacterpylori and cytomegalovirus are not Epidemiol
106. Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases
107. Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic tissue
108. Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections
109. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients
110. Chlamydia pneumoniae serology: Interlaboratory variation in microimmunofluorescence assay results
111. Inter-laboratory comparison of microimmuno-fluorescence results
112. Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci
113. Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae
114. Chlamydia pneumoniae in human abdominal aortic aneurysms
115. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis
116. Quinolones in sexually transmitted diseases
117. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
118. Inflammation, infection, and cardiovascular risk. How good is the clinical evidence?
119. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction
120. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women
121. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia
122. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia
123. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
124. Enterovirus infections as a possible risk factor for myocardial infection
125. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae
126. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
127. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study
128. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin
129. The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease
130. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques
131. Chlamydia pneumoniae in atheroma: Consideration of criteria for causality
132. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production
133. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The cardiovascular health study
134. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study
135. Chlamydia pneumoniae in vascular tissues from heart-transplant donors
136. Chlamydia pneumoniae in arteries: The facts, their interpretation, and future studies
137. Coronary heart disease and Chlamydia pneumoniae DNA in blood mononuclear cells
138. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease
139. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease
140. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque
141. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease
142. The use of serologic tests for the diagnosis of chlamydial infections
143. Age-related inerference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor
144. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: Large, prospective study
145. The microimmunofluorescence test for Chlamydia pneumoniae infection: Technique and interpretation
146. IgA antibody response on Chlanmydia pneumoniae (TWAR) infection
147. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy
148. Chlamydia pneumoniae does not promote atherosclerosis in a mouse model
149. Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions
150. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery
151. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease
152. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae
153. Infectious agents are not necessary for murine atherogenesis
154. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery